Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-05-25

FDA Approved: QUINAPRIL AND HYDROCHLOROTHIAZIDE 10/12.5 — Supplemental Application (Cipla USA Inc.)

View source ↗

Summary

The FDA approved Cipla USA Inc.'s supplemental application for Quinapril and Hydrochlorothiazide in strengths 10/12.5, 20/12.5, and 20/25.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • QUINAPRIL AND HYDROCHLOROTHIAZIDE 10/12.5 (Quinapril and Hydrochlorothiazide)
  • QUINAPRIL AND HYDROCHLOROTHIAZIDE 20/12.5 (Quinapril and Hydrochlorothiazide)
  • QUINAPRIL AND HYDROCHLOROTHIAZIDE 20/25 (Quinapril and Hydrochlorothiazide)

Snippet

SUPPL AP for QUINAPRIL AND HYDROCHLOROTHIAZIDE 10/12.5 (QUINAPRIL AND HYDROCHLOROTHIAZIDE 10/12.5)